Navigation Links
WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2009 Results
Date:3/8/2010

SHANGHAI, China, March 8 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for fourth-quarter and full-year 2009.

    (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

    Fourth-Quarter 2009 Highlights

    -- Net revenues grew 15% year over year to $73.9 million
    -- Laboratory Services net revenues increased 18% year over year to $67.5
       million
    -- China-based Laboratory Services net revenues grew 21% year over year to
       $51.4 million
    -- U.S.-based Laboratory Services net revenues increased 7% year over year
       to $16.2 million
    -- Manufacturing Services net revenues decreased 10% year over year to
       $6.3 million
    -- GAAP diluted earnings per ADS was 16 cents, versus a loss in the
       prior-year period
    -- Non-GAAP diluted earnings per ADS grew 56% year over year to 22 cents

    Full-Year 2009 Highlights

    -- Net revenues grew 7% year over year to $270.0 million
    -- Laboratory Services net revenues increased 22% year over year to $249.9
       million
    -- China-based Laboratory Services net revenues grew 26% year over year to
       $185.8 million
    -- U.S.-based Laboratory Services net revenues increased 2% year over year
       on a pro-forma basis to $64.1 million
    -- Manufacturing Services net revenues decreased 58% year over year to
       $20.1 million
    -- GAAP diluted earnings per ADS was 72 cents, versus a loss in the
       prior-year period
    -- Non-GAAP diluted earnings per ADS grew 11% year over year to 89 cents

Management Comment

"WuXi had a strong fourth quarter and a successful 2009," said Dr. Ge Li, Chairman and Chief Executive Officer. "We achieved all of our publicly stated financial goals. We were able to achieve solid revenue growth in 2009, led by a strong performance by our China-based Laboratory Services business, which achieved revenues at the top of its guidance range. Full-year 2009 adjusted EBITDA(1) exceeded our expectations.

"We expect another good year in 2010. We are targeting 2010 revenues to grow 15-19% above 2009 levels, driven by 13-16% growth in revenues of our China-based Laboratory Services business and an improving Manufacturing Services business. We believe that these rates of growth remain at or near the top of our industry. At the same time, 2010 will be a transition year, as we continue to invest in our China-based Laboratory Services, large-scale manufacturing, and toxicology businesses. In spite of these investments, operating income in 2010 will grow by up to 10%. We expect these investments will drive accelerating growth in revenues and operating income in 2011 and beyond.

"Improving R&D productivity is the most important challenge facing the world's pharmaceutical, biotech, and medical device companies. Outsourcing and offshoring enable these companies to obtain high-quality R&D services to advance compounds faster and at lower cost. As a leader in providing customers with high-quality outsourced R&D services, WuXi has been building a broad platform of fully integrated, cost-effective drug discovery and development services with the mission of helping our partners to improve the success of discovery and shorten the time of development. We expect that trends favoring greater R&D outsourcing and offshoring and greater use of integrated services will expand over the next decade, and that WuXi and its partners will both benefit from this trend," Dr. Li concluded.

    (1) Refer to Reconciliation of GAAP to Non-GAAP and Use of Non-GAAP
        Financial Measures included in this release.

GAAP Results -- Fourth-Quarter 2009

Fourth-quarter 2009 net revenues increased 15% year over year to $73.9 million due to 18% growth in Laboratory Services net revenues, partially offset by a 10% decline in Manufacturing Services net revenues. Revenue growth was strong in both discovery chemistry and newer laboratory services, such as discovery biology, DMPK/ADME, formulation, and bio-analytical services. Growth was achieved under both full-time-equivalent and fee-for-service contracts.

Fourth-quarter 2009 GAAP gross profit increased 44% year over year to $29.2 million, mainly due to an increased contribution from Laboratory Services, driven by both revenue growth and gross-margin improvement, offset by a decline in the gross-profit contribution of Manufacturing Services from lower revenues and lower gross margin. Fourth-quarter 2009 GAAP gross margin improved year over year to 39.6% from 31.5%, mainly due to lower amortization expenses for acquired intangible assets as a result of a lower balance for these assets following impairment charges relating to AppTec taken in fourth-quarter 2008. GAAP gross margin also benefited from a larger contribution from our higher-margin Laboratory Services business. Gross margin from Laboratory Services improved year over year to 41.7% from 32.8% due to lower amortization expenses for acquired intangible assets and improved profitability of newer downstream laboratory services, offset by increased expenses related to the ramp-up of the Suzhou toxicology facility. Partially offsetting this benefit, gross margin declined year over year in Manufacturing Services to 16.7% from 20.5% due primarily to unfavorable project mix and lower demand.

Fourth-quarter 2009 GAAP operating income was $13.6 million compared to an operating loss of $56.7 million in the prior-year period due to the 44% increase in gross profit, a 5% decrease in SG&A expenses, and a $60.5 million impairment charge relating to the AppTec acquisition recorded in the prior-year period.

Fourth-quarter 2009 GAAP net income from continuing operations was $12.5 million compared to a loss of $49.2 million in the prior-year period due to the improvement in operating income, offset by higher taxes and an unfavorable change in other income (expenses) net. Higher taxes were mainly the result of tax benefits in the prior year related to impairment charges for AppTec. Other income (expenses) net in fourth-quarter 2009 included foreign-exchange losses of $0.2 million, compared to $1.0 million of foreign-exchange gains in fourth-quarter 2008.

Fourth-quarter 2009 GAAP net income was $12.1 million compared to a loss of $93.9 million in the prior-year period due to the improvement in net income from continuing operations and a smaller loss from discontinued operations. Fourth-quarter 2008 GAAP net income included a loss from continuing operations of $49.2 million and an after-tax loss from discontinued operations of $44.6 million related to the closedown of the biologics manufacturing operation in our Philadelphia facility. The loss from discontinued operations in fourth-quarter 2009 of $0.4 million resulted from a write-off of certain obsolete assets and impairment of certain assets held for sale. Fourth-quarter 2009 GAAP diluted earnings per ADS was 16 cents, compared to a loss of $1.42 in fourth-quarter 2008.

GAAP Results -- Full-Year 2009

Full-year 2009 net revenues increased 7% year over year to $270.0 million due to 22% growth in Laboratory Services net revenues, partially offset by a 58% decline in Manufacturing Services net revenues. Revenue growth was strong in both discovery chemistry and newer laboratory services, such as discovery biology, DMPK/ADME, formulation, and bio-analytical services. Growth was achieved under both full-time-equivalent and fee-for-service contracts.

Full-year 2009 GAAP gross profit increased 13% year over year to $108.4 million, mainly due to an increased contribution from Laboratory Services, driven by both revenue growth and gross-margin improvement, offset by a decline in the gross-profit contribution of Manufacturing Services from lower revenues and lower gross margin. Full-year 2009 GAAP gross margin improved year over year to 40.1% from 38.0%, mainly due to lower amortization expenses for acquired intangible assets as a result of a lower balance for these assets following impairment charges relating to the AppTec acquisition taken in fourth-quarter 2008. In addition, GAAP gross margin benefited from a larger contribution from our higher-margin Laboratory Services business. Gross margin from Laboratory Services improved year over year to 41.9% from 39.2% due to lower amortization expenses for acquired intangible assets and improved profitability of newer downstream laboratory services, offset by increased expenses related to the ramp-up of the Suzhou toxicology facility. Partially offsetting this benefit, gross margin declined year over year in Manufacturing Services to 18.1% from 33.1% due primarily to unfavorable project mix and lower demand.

Full-year 2009 GAAP operating income was $52.1 million compared to an operating loss of $20.9 million in the prior year due primarily to the 13% increase in gross profit and a $60.5 million impairment charge relating to AppTec recorded in the prior year.

Full-year 2009 GAAP net income from continuing operations was $53.4 million compared to a loss of $15.0 million in the prior year due to the improvement in operating income and a favorable change in other income (expenses) net, offset by higher taxes. Higher taxes were mainly the result of tax benefits in the prior year related to impairment charges relating to AppTec. Other income (expenses) net in full-year 2009 included foreign-exchange gains of $3.8 million, compared to $0.4 million of foreign-exchange gains in full-year 2008.

Full-year 2009 GAAP net income was $52.9 million compared to a loss of $64.2 million in the prior year due to the improvement in net income from continuing operations and a smaller loss from discontinued operations. Full-year 2008 GAAP net income included a loss from continuing operations of $15.0 million and an after-tax loss from discontinued operations of $49.3 million related to the closedown of the biologics manufacturing operation in our Philadelphia facility. The loss from discontinued operations in 2009 of $0.6 million resulted from impairment and write off of certain assets held for sale. Full-year 2009 GAAP diluted earnings per ADS was 72 cents, compared to a loss of $1.01 in full-year 2008, due primarily to the net losses from continuing operations and from discontinued operations in the prior year, mainly driven by impairment charges.

Non-GAAP Results -- Fourth-Quarter 2009

Non-GAAP financial results excluded the impact of share-based compensation expenses, amortization and the deferred tax impact of acquired intangible assets, impairment charges, and losses from discontinued operations.

Fourth-quarter 2009 non-GAAP gross profit increased 23% year over year to $30.8 million, mainly due to revenue growth and improved gross margin. Fourth-quarter 2009 non-GAAP gross margin increased year over year to 41.7% from 39.1% due to improved gross margin in the Laboratory Services business and the larger relative contribution of this higher-margin Laboratory Services business. The benefit was partially offset by increased operating costs of the Suzhou toxicology facility and a decline in the gross-profit contribution from Manufacturing Services due to lower revenues and lower gross margin.

Fourth-quarter 2009 non-GAAP operating income increased 54% year over year to $17.3 million, primarily due to the 23% increase in non-GAAP gross profit and a 3% decrease in operating expenses due to cost control.

Fourth-quarter 2009 non-GAAP net income grew 59% year over year to $16.0 million due to a 54% increase in non-GAAP operating income and lower taxes, offset by an unfavorable change in other income (expenses) net. Taxes were lower due to tax planning initiatives. Changes in other income (expenses) net and taxes are discussed above for GAAP results. Diluted non-GAAP earnings per ADS from continuing operations grew 56% year over year to 22 cents compared to 14 cents in fourth-quarter 2008, mainly due to the 59% increase in non-GAAP net income.

Non-GAAP Results -- Full-Year 2009

Full-year 2009 non-GAAP gross profit increased 3% year over year to $114.1 million, mainly due to revenue growth, offset by lower gross margin. Full-year 2009 non-GAAP gross margin decreased year over year to 42.3% from 43.6% due to a decline in the gross margin from Manufacturing Service from project mix and lower demand, a decline in gross margin of the Laboratory Services business due to the impact of increasing operating costs from the Suzhou toxicology facility and a decline in the U.S.-based Laboratory Services business due to project mix, partially offset by the positive impact from the larger relative contribution of this higher-margin Laboratory Services business. Within Laboratory Services, improved profitability of newer laboratory services more than offset the impact of increasing operating costs from the Suzhou toxicology facility.

Full-year 2009 non-GAAP operating income increased 3% year over year to $65.4 million, primarily due to the 3% increase in non-GAAP gross profit and a 4% increase in operating expenses.

Full-year 2009 non-GAAP net income grew 12% year over year to $65.5 million due to a 3% increase in non-GAAP operating income, a favorable change in other income (expenses) net, and lower taxes. Taxes were lower due to tax planning initiatives in 2009. Changes in other income (expenses) net are discussed above for GAAP results. Diluted non-GAAP earnings per ADS from continuing operations grew 11% year over year to 89 cents compared to 80 cents in full-year 2008, mainly due to the 12% increase in non-GAAP net income.

(See the table titled Reconciliation of GAAP to Non-GAAP below).

Performance Versus 2009 Financial Guidance

The company's full-year 2009 performance versus its financial guidance was as follows:

    -- Total net revenues of $270.0 million fell within the expected range of
       $265-$275 million
    -- Growth in 2009 net revenues of China-based Laboratory Services of 26%
       came in at the top of the expected range of 23-26%
    -- 2009 net revenues of U.S.-based Laboratory Services of $64.1 million
       represented a slight increase compared to 2008 net revenues on a
       pro-forma basis of $62.7 million, as expected
    -- 2009 Manufacturing Services net revenues of $20.1 million fell within
       the expected range of $20-$30 million.  A large order is expected to be
       delivered in the first quarter, and we now project first-quarter 2010
       Manufacturing Services net revenues of $12-$14 million.
    -- 2009 adjusted EBITDA (excluding share-based compensation charges and
       potential mark-to-market gains or losses from foreign-currency forward
       contracts) of $92.3 million exceeded the expected range of $86-$90
       million

    2010 Financial Guidance
    The company projects 2010 financial performance as follows:

    -- Total net revenues of $310-320 million, which represents 15-19% growth
    -- Growth in net revenues of China-based Laboratory Services of 13-16%
    -- Growth rate of net revenues of U.S.-based Laboratory Services of mid
       single digits
    -- Growth of net revenues of Manufacturing Services of at least 70%
    -- Decline in GAAP and non-GAAP gross margin of two to five percentage
       points
    -- Growth in GAAP and non-GAAP operating income of up to 10%
    -- Capital expenditures of $50-60 million, similar to the 2009 level
    -- Effective tax rate of 13-15%

Commenting on 2010 guidance, Edward Hu, chief operating officer and acting chief financial officer, said, "In 2010, we expect continued solid financial performance while we invest for the future. We expect that growth in total net revenues will significantly accelerate from 7% in 2009 to 15-19% in 2010, driven by broad-based demand for our integrated services platform. China Laboratory Services is expected to achieve revenue growth of 13-16%. Manufacturing Services revenues are expected to grow more than 70% year over year in 2010, benefiting from a large delivery in the first quarter and from generally improving demand. Revenues in U.S.-based Laboratory Services are expected to grow at a mid-single-digit rate. These projections assume very small revenue contributions from the large-scale manufacturing and toxicology businesses in 2010.

"Operating income in 2010 is expected to achieve growth of up to 10 percent compared to 2009, driven by strong revenue growth and increased leverage of SG&A. An expected 2-5 percentage point gross margin decrease, primarily in the second half of 2010, is due to several factors, including an increase in labor and depreciation expenses, expenses from the ramp-up of the toxicology and large-scale GMP manufacturing operations, and pricing pressure. We are working to improve our projected 2010 gross margins. We expect the growth rate in operating income to accelerate in 2011, driven by continued strong revenue growth from China-based laboratory services, meaningful revenues from toxicology and large-scale manufacturing, and improving margins."



                          WUXI PHARMATECH (CAYMAN) INC.
                      UNAUDITED CONSOLIDATED BALANCE SHEETS
            (in thousands of U.S. dollars, except ordinary share,
                             ADS and par value data)

                                                   December 31,   December 31,
                                                       2009            2008

    Assets:
    Current assets:
      Cash and cash equivalents                       80,510          56,624
      Restricted cash                                  1,358           1,338
      Short-term investment                           22,083          14,631
      Accounts receivable, net                        45,817          36,457
      Inventories                                     14,276           6,926
      Prepaid expenses and other current assets       10,125           7,281
      Assets of discontinued operations (Note 1)          --           6,508
        Total current assets                         174,169         129,765
    Non-current assets:
      Goodwill                                        23,956          23,956
      Property, plant and equipment, net             181,830         152,704
      Intangible assets, net                           6,634           9,934
      Prepaid land use rights                          5,308           5,424
      Deferred tax assets                              9,514           8,807
      Other non-current assets                         5,890           5,809
        Total non-current assets                     233,132         206,634

        Total assets                                 407,301         336,399

    Liabilities and shareholders' equity:
    Current liabilities:
      Short-term and current portion of
       long-term debt                                 34,415           7,558
      Accounts payable                                14,356          19,829
      Accrued expenses                                17,072          14,279
      Deferred revenue                                 4,554           3,373
      Advanced subsidies                               2,800           3,080
      Other taxes payable                              2,901           5,742
      Other current liabilities                        4,239           3,448
      Liabilities of discontinued operations
       (Note 1)                                           --           1,495
        Total current liabilities                     80,337          58,804
    Non-current liabilities:
      Long-term debt, excluding current
       portion                                         2,115           2,305
      Advanced subsidies                               1,420           1,819
      Convertible notes                               35,864          35,864
      Other non-current liabilities                    7,432           6,731
        Total non-current liabilities                 46,831          46,719

        Total liabilities                            127,168         105,523

    Shareholders' equity:
      Ordinary shares ($0.02 par value,
       5,002,500,000 authorized as of
       December 31, 2009, and December 31,
       2008, respectively; 550,609,256
       and 529,385,590 issued and outstanding
       as of December 31, 2009, and
       December 31, 2008, respectively)               11,012          10,588
      Additional paid-in capital                     320,672         324,629
      Accumulated deficit                            (68,631)       (121,505)
      Accumulated other comprehensive income          17,080          17,164
        Total shareholders' equity                   280,133         230,876

        Total liabilities and shareholders'
         equity                                      407,301         336,399

     Note 1: The biologics manufacturing operations in Philadelphia, which
     management decided to close in December 2008, were classified
     as discontinued operations.



                          WUXI PHARMATECH (CAYMAN) INC.
            UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
        (In thousands of U.S. dollars, except ADS data and per ADS data)

                             Three Months Ended        Twelve Months Ended
                                December 31,                December 31,
                                                               2008
                         2009      2008   % Change   2009    (Note 2) % Change
    Net revenues:
      Laboratory
       Services         67,540    57,423     18%   249,909    205,028     22%
      Manufac-
       turing
       Services          6,337     7,025    (10%)   20,110     48,457    (58%)
        Total net
         revenues       73,877    64,448     15%   270,019    253,485      7%
    Cost of
     revenues:
      Laboratory
       Services        (39,363)  (38,591)     2%  (145,153)  (124,723)    16%
      Manufac-
       turing
       Services         (5,278)   (5,583)    (5%)  (16,461)   (32,420)   (49%)
        Total
         cost of
         revenues      (44,641)  (44,174)     1%  (161,614)  (157,143)     3%
    Gross profit:
      Laboratory
       Services         28,177    18,832     50%   104,756     80,305     30%
      Manufac-
       turing
       Services          1,059     1,442    (27%)    3,649     16,037    (77%)
        Total
         gross
         profit         29,236    20,274     44%   108,405     96,342     13%
    Operating
     expenses:
      Selling and
       marketing
       expenses         (2,129)   (2,156)    (1%)   (7,447)    (7,371)     1%
      General and
       admini-
       strative
       expenses        (13,520)  (14,321)    (6%)  (48,829)   (49,400)    (1%)
      Impairment
       charge               --   (60,497)  (100%)       --    (60,497)  (100%)
        Total
         operating
         expenses      (15,649)  (76,974)   (80%)  (56,276)  (117,268)   (52%)

    Operating
     income             13,587   (56,700)      *    52,129    (20,926)      *
    Other income
     (expenses), net:
      Other income
       (expenses),
       net               (453)     1,586       *     6,776      1,046       *
      Interest
       income
       (expenses),
       net                102        270    (62%)       57        913    (94%)
        Total other
         income
         (expenses),
         net             (351)     1,856       *     6,833      1,959       *
    Income from
     continuing
     operations
     before
     income
     taxes             13,236    (54,844)      *    58,962    (18,967)      *

    Income tax
     (expenses)
     benefit             (725)     5,605       *    (5,530)     4,016       *

    Income from
     continuing
     operations        12,511    (49,239)      *    53,432    (14,951)      *
    Loss on
     discontinued
     operations,
     net (Note 1)
      Loss from
       operations
       of dis-
       continued
       component         (631)   (54,290)   (99%)     (944)   (61,665)   (98%)
      Income tax
       benefit            247      9,678    (97%)      386     12,413    (97%)
    Loss on dis-
     continued
     operations          (384)   (44,612)   (99%)     (558)   (49,252)   (99%)
    Net income         12,127    (93,851)      *    52,874    (64,203)      *

    Basic net
     earnings
     (loss) per
     ADS:
    Earnings from
     continuing
     operations         $0.18     ($0.74)      *     $0.79     ($0.23)      *
    Loss on dis-
     continued
     operations
     - net of tax
     (Note 1)           (0.01)    ($0.68)   (99%)    (0.01)    ($0.78)   (99%)
    Net earnings
     per ADS            $0.17     ($1.42)      *     $0.78     ($1.01)      *

    Weighted
     average
     ADS out-
     standing
     - basic       68,659,814  66,035,918       67,986,475 63,775,220

    Diluted net
     earnings
     (loss) per
     ADS:
    Earnings
     from
     continuing
     operations         $0.17      ($0.74)     *     $0.73     ($0.23)      *
    Loss on dis-
     continued
     operations
     - net of tax
     (Note 1)           (0.01)     ($0.68)  (99%)    (0.01)    ($0.78)   (99%)
    Net earnings
     per ADS            $0.16      ($1.42)     *     $0.72     ($1.01)      *

    Weighted
     average
     ADS out-
     standing
     - diluted     74,080,635  66,035,918       73,654,710 63,775,220

    *  >100% or not meaningful

    Note 2: Financial results of AppTec were consolidated as of January 31,
     2008.




                          WUXI PHARMATECH (CAYMAN) INC.
                        RECONCILIATION OF GAAP TO NON-GAAP
         (in thousands of U.S. dollars, except ADS data and per ADS data)

                       Three Months Ended           Twelve Months Ended
                          December 31,                  December 31,
                        2009       2008      %       2009       2008      %
    GAAP gross
     profit
     -continuing
     operations        29,236      20,274    44%   108,405     96,342     13%
    GAAP gross
     margin
     -continuing
     operations           40%         31%              40%        38%
    Adjustments:
      Share-based
       compensation       842       1,004            2,685      3,020
      Amortization of
       acquired
       intangible
       assets             764       3,896            3,057     11,175
    Non-GAAP gross
     profit            30,842      25,174    23%   114,147    110,537      3%
    Non-GAAP gross
     margin               42%         39%              42%        44%

    GAAP operating     13,587    (56,700)      *    52,129    (20,926)      *
     income-
     continuing
     operations
    GAAP operating        18%       (88%)      *       19%        (8%)      *
     margin-
     continuing
     operations
    Adjustments:
      Share-based
       compensation     2,972      3,521            10,220     13,046
      Amortization of
       acquired
       intangible
       assets             764      3,896             3,057     11,175
      Impairment
       charge                     60,497                       60,497
    Non-GAAP
     operating
     income            17,323     11,214     54%    65,406     63,792      3%
    Non-GAAP
     operating
     margin               23%        17%               24%        25%

    GAAP net income
     -continuing
     operations        12,511    (49,239)      *    53,432    (14,951)      *
    GAAP net margin
     -continuing
     operations           17%       (76%)              20%        (6%)
    Adjustments:
      Share-based
       compensation     2,972      3,521            10,220     13,046
      Amortization of
       acquired
       intangible
       assets             764      3,896             3,057     11,175
      Impairment
       charge                     60,497                       60,497
      Deferred tax
       impact related
       to acquired
       intangible
       assets            (296)    (8,648)           (1,184)   (11,502)
    Non-GAAP net
     income            15,951     10,027     59%    65,525     58,265     12%
    Non-GAAP net
     margin               22%        16%               24%        23%

    GAAP net income    12,127    (93,851)      *    52,874    (64,203)      *
    Add back:
      Depreciation
       and amorti-
       zation           6,726      6,264            23,974     30,587
      Interest
       (income)
       expenses, net     (102)      (270)              (57)      (913)
      Income tax
       expenses
       (benefit)          478    (15,283)            5,143    (16,429)
    EBITDA             19,229   (103,140)      *    81,934    (50,958)      *
    Adjustments:
      Share-based
       compensation     2,972      3,521            10,220     13,046
      Mark-to-market    1,226        626              (481)     2,758
       losses (gains)
       on foreign-
       exchange
       forward
       contracts
      Impairment
       charge
       -continuing
       operations                 60,497                       60,497
      Impairment
       charge-dis-
       continued
       operations         591     49,581               591     49,581
    Adjusted EBITDA    24,018     11,085       *    92,264     74,924     23%

    Income attri-
     butable to
     holders of ADS
     (Non-GAAP):
    Basic              15,951     10,027     59%    65,525     58,265     12%
    Diluted            15,951     10,027     59%    65,525     58,265     12%

    Basic earnings
     per ADS
     (Non-GAAP)          0.23       0.15     53%      0.96       0.91      5%
    Diluted
     earnings per
     ADS (Non-GAAP)      0.22       0.14     56%      0.89       0.80     11%

    Weighted
     average ADS
     outstanding
     - basic
     (Non-GAAP)    68,659,814 66,035,918        67,986,475 63,775,220
    Weighted
     average ADS
     outstanding
     - diluted
     (Non-GAAP)    74,080,635 72,679,824        73,654,710 72,896,204



                          WUXI PHARMATECH (CAYMAN) INC.
                                REVENUE BREAKDOWN
                          (in thousands of U.S. dollars)

                              Three Months Ended         Twelve Months Ended
                                  December 31,                December 31,
                            2009     2008       %       2009     2008      %
    Net revenues:
      China-based
       Laboratory
       Services            51,364   42,286     21%    185,799  147,333    26%
      U.S.-based
       Laboratory
       Services*           16,176   15,137      7%     64,110   57,695    11%
        Subtotal           67,540   57,423     18%    249,909  205,028    22%
      China-based
       Manufacturing
       Services             6,337    7,025    (10%)    20,110   48,457   (58%)
    Total net
     revenues              73,877   64,448     15%    270,019  253,485     7%


    * Only eleven months of revenues (February to December 2008) were included
    in 2008 for U.S.-based Laboratory Services because that business was
    acquired on January 31, 2008.

Conference Call

WuXi PharmaTech senior management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 9:00 pm (Beijing/Shanghai/Hong Kong) on Tuesday, March 9, 2010, to discuss its fourth-quarter 2009 financial results and future prospects. The conference call may be accessed by calling:

    United States:    1-866-519-4004
    China (Landline): 800-819-0121
    China (Mobile):   400-620-8038
    Hong Kong:        800-930-346
    United Kingdom:   0-808-234-6646
    International:    +65-6735-7955
    Conference ID:    57898803

    A telephone replay will be available two hours after the call's completion
at:

    United States:    1-866-214-5335
    China North:      10-800-714-0386
    China South:      10-800-140-0386
    Hong Kong:        800-901-596
    United Kingdom:   0-800-731-7846
    International:    +61-2-8235-5000
    Conference ID:    57898803

A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech's website at http://www.wuxiapptec.com .

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

Use of Non-GAAP Financial Measures

We have provided the fourth-quarter and full-year 2008 and 2009 gross profit, operating income, net income, and earnings per ADS on a non-GAAP basis, which excludes share-based compensation expenses, amortization and deferred tax impact of acquired intangible assets, and results from discontinued operations. We believe both management and investors benefit from referring to these non-GAAP and pro-forma financial measures in assessing our financial performance and liquidity and when planning and forecasting future periods. These non-GAAP operating measures are useful for understanding and assessing underlying business performance and operating trends. We expect to continue to provide net income and earnings per ADS on a non-GAAP basis using a consistent method on a quarterly basis.

You should not view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies, and should refer to the reconciliation of GAAP measures to non-GAAP measures for the indicated periods attached hereto.

Cautionary Note Regarding Forward-Looking Statements

Statements in this release contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995, including, among others, among others, our financial guidance for first quarter 2010 and full year 2010 (including, as applicable, estimated total net revenues, China-based Laboratory Services net revenues, Manufacturing Services net revenues, operating income, adjusted EBITDA, gross margins, and other trends) and outlook for 2011 (including expected growth in China-based laboratory services, improving margins and meaningful revenues for various service areas) and the factors driving each; planned capital expenditure and investment levels, and the anticipated benefits of those efforts and the planned expansion of our service offerings and areas of related revenue growth.

These forward-looking statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. Our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Among other factors, continued uncertainty in the global economy and the pressures being felt by our customers and pharmaceutical industry consolidation may adversely impact our business and the trends for outsourced R&D and manufacturing for longer than expected or more severely than expected; we may be unable to successfully make our planned investments and capital expenditures on a timely basis, these investments may not yield the desired results, and we may need to modify the nature and level of our investments and capital expenditures; pharmaceutical companies may not change their business models as expected or in a manner favorable to us; we may fail to capitalize on the opportunities presented; we may not maintain our preferred provider status with our clients; and may be unable to successfully expand our capabilities to meet client needs. In addition, other factors that could cause our actual results to differ from what we currently anticipate include our limited operating history; failure to generate sufficient future cash flows or secure any required future financing on acceptable terms or at all; failure to retain key personnel; our reliance on a limited number of customers to continue to account for a high percentage of our revenues; risk of payment failure by any of our large customers, which could significantly harm our cash flows and profitability; dependence upon the continued service of our senior management and key scientific personnel, and our ability to retain our existing customers or expand our customer base. You should read the financial information contained in this release in conjunction with the consolidated and pro-forma financial statements and related notes thereto included in our 2008 Annual Report on Form 20-F filed with and available on the Securities and Exchange Commission's website at http://www.sec.gov. For additional information on these and other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 6 of our 2008 Annual Report on Form 20-F. Our results of operations for fourth-quarter and full year 2009 are not necessarily indicative of our operating results for any future periods. All projections in this release are based on limited information currently available to us, which is subject to change. Although these projections and the factors influencing them will likely change, we undertake no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release, except as required by law. Such information speaks only as of the date of this release.

    For more information, please contact:

    WuXi PharmaTech (Cayman) Inc.

     Ronald Aldridge (for investors)
     Director of Investor Relations
     Tel:   +1-201-585-2048
     Email: ir@wuxiapptec.com

     Stephanie Liu (for the media)
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +86-21-5046-4362
     Email: pr@wuxiapptec.com

SOURCE WuXi PharmaTech (Cayman) Inc.

Back to top

RELATED LINKS
http://www.wuxiapptec.com

'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. WuXi PharmaTech (NYSE: WX) Holds Its Third Life Science and Chemistry Awards Ceremony in Beijing
2. WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening
3. WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year
4. Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline
5. WuXi PharmaTech Announces Second-Quarter 2009 Results
6. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting
7. WuXi PharmaTech Schedules Second-Quarter 2009 Earnings Release
8. WuXi PharmaTech Receives Award from BASF
9. WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise
10. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
11. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 10, 2016  IsoRay, Inc. (NYSE MKT: ISR), a ... medical radioisotope applications for the treatment of prostate, brain, ... its financial results for the second quarter and six ... --> --> ... fiscal 2016, which ended December 31, 2015, a 12% ...
(Date:2/10/2016)... Texas (PRWEB) , ... February 10, 2016 , ... ... centers across three states, announced today the promotion of two long-standing principal investigators ... Chief of Family Medicine, Clinical Research and Development. , Dr. Laurence Chu, a ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... their comprehensive training and support program, Sonalinkā„¢ remote monitoring. The inaugural launch of ... on Friday, February 5th, connecting Dr. Samuel Peretsman to a HIFU technical expert ...
(Date:2/10/2016)... ... 10, 2016 , ... Global Stem Cells Group, ... Global Stem Cells Network (GSCN) and its affiliate Global Medical Training Network ... adipose and bone marrow therapies. , Through the new collaboration, Global Stem ...
Breaking Biology Technology:
(Date:2/8/2016)... Czech Republic , February 8, 2016 /PRNewswire/ ... EU-regulated global payment platform which presents innovation for ... Biometrics Authentication feature called VoiceKey. --> ... platform which presents innovation for clients, comfort and ... called VoiceKey. --> Worldcore ...
(Date:2/4/2016)... -- The field of Human Microbiome research and ... hubs of the biotechnology industry. While the Human ... human microbiota, have garnered a lot of attention ... has literally exploded in terms of both basic ... on biomedical aspects of research, development, and commercial ...
(Date:2/3/2016)... -- --> --> ... Identification System Market by Component (Hardware and Software), Search ... Government, Healthcare, and Transportation) and Geography - Global Forecast ... to be worth USD 8.49 Billion by 2020 at ... The transformation and technology evolution from the manual process ...
Breaking Biology News(10 mins):